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Oxidized LDLWestudiedwhether PPARβ/δdeﬁciencymodiﬁes the effects of high fructose intake (30% fructose in drinkingwater)
on glucose tolerance and adipose tissue dysfunction, focusing on the CD36-dependent pathway that enhances
adipose tissue inﬂammation and impairs insulin signaling. Fructose intake for 8 weeks signiﬁcantly increased
body and liver weight, and hepatic triglyceride accumulation in PPARβ/δ-deﬁcient mice but not in wild-type
mice. Feeding PPARβ/δ-deﬁcientmicewith fructose exacerbated glucose intolerance and led tomacrophage inﬁltra-
tion, inﬂammation, enhancedmRNA and protein levels of CD36, and activation of the JNK pathway inwhite adipose
tissue compared to those of water-fed PPARβ/δ-deﬁcient mice. Cultured adipocytes exposed to fructose also exhib-
ited increased CD36 protein levels and this increase was prevented by the PPARβ/δ activator GW501516. Interest-
ingly, the levels of the nuclear factor E2-related factor 2 (Nrf2), a transcription factor reported to up-regulate Cd36
expression and to impair insulin signaling, were increased in fructose-exposed adipocytes whereas co-incubation
withGW501516 abolished this increase. In agreementwithNrf2 playing a role in the fructose-induced CD36protein
level increases, the Nrf2 inhibitor trigonelline prevented the increase and the reduction in insulin-stimulated
AKT phosphorylation caused by fructose in adipocytes. Protein levels of the well-known Nrf2 target gene
NAD(P)H:quinone oxidoreductase 1 (Nqo1) were increased in water-fed PPARβ/δ-null mice, suggesting that
PPARβ/δ deﬁciency increases Nrf2 activity; and this increase was exacerbated in fructose-fed PPARβ/δ-deﬁcient
mice. These ﬁndings indicate that the combination of high fructose intake and PPARβ/δ deﬁciency increases CD36
protein levels via Nrf2, a process that promotes chronic inﬂammation and insulin resistance in adipose tissue.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The drastic increase in the incidence of obesity and type 2 diabetes
mellitus observed in Western countries over recent decades has coin-
cided with an increase in total energy consumption and a shift in the
types of nutrients ingested. This includes a dramatic increase in the
consumption of fructose, used in processed or prepared foods and
caloric beverages [1]. Strong evidence suggests that diets high in fruc-
tose result in hepatic steatosis, hyperlipidemia and insulin resistance
[2,3]. Unlike glucose, which is widely used by tissues throughout thenitat de Farmacologia, Facultat
l.: +34 93 402 4531; fax: +34
z-Carrera).body, fructose is mainly metabolized in the liver, where it increases de
novo lipogenesis [4]. As a result, the effects of fructose overconsumption
have mainly been studied in liver. However, high fructose intake is also
associated with adiposity [2,3]. In fact, in a recent study conducted in
adolescents, greater fructose consumptionwas associatedwithmultiple
markers known to increase the risk of cardiovascular disease and type 2
diabetes mellitus, and it appeared that these relationships were
dependent on visceral adiposity [5].
The nuclear receptor peroxisome proliferator-activated receptor
(PPAR)β/δ is an important regulator of lipid and energy metabolism in
adipose tissue and skeletal muscle [6,7]. Therefore, PPARβ/δ represents
a candidate mediator of insulin resistance and type 2 diabetes mellitus,
and a promising target for the prevention and treatment of these dis-
eases [6,8]. Thus, a reduction in PPARβ/δ activity can contribute to
inﬂammation and insulin resistance. For instance, genetic variation in
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type 2 diabetes mellitus [9]. In addition, we recently reported that in
severely obese insulin-resistant patients, enhanced inﬂammation in
visceral adipose tissue was accompanied by an increase in PPARβ/δ
mRNA levels. This increase in the expression of PPARβ/δ seems to be a
compensatory mechanism since PPARβ/δ activity was reduced in
human cultured adipocytes exposed to inﬂammatory stimuli [10].
Overall, these ﬁndings suggest the hypothesis that PPARβ/δ plays a
central role in metabolic regulation and its deﬁciency might contribute
to exacerbating metabolic derangements caused by fructose.
The aim of thisworkwas to studywhether PPARβ/δ deﬁciencymod-
iﬁes the effects of a high fructose intake (30% fructose solution as the
only ﬂuid source) on glucose tolerance and adipose tissue dysfunction.
We focused on the CD36-dependent pathway that enhances adipose
tissue inﬂammation and impairs insulin signaling [11]. This class B
scavenger receptor recognizes a variety of ligands, including oxidized
LDL (oxLDL), which contribute to the pathogenesis of insulin resistance.
In fact, CD36 is highly expressed in adipocyteswhere it drives an inﬂam-
matory processwhich involves the activation of c-JunN-terminal kinase
(JNK) and the consequent disruption of insulin signaling [11]. These
changes are dependent on CD36 since its absence protects mice from
insulin resistance associated with diet-induced obesity [11].
Interestingly, activation of the nuclear factor E2-related factor 2
(Nrf2), one of themost regulated defensemechanisms against oxidative
stress, upregulates Cd36 expression [12] and impairs insulin signaling
and glucose uptake [13]. Under physiological conditions, Nrf2 binds to
Kelch-like ECH associating protein (Keap 1) in the cytoplasm. On expo-
sure to oxidative stress, Nrf2 releases from Keap 1, translocates to the
nucleus and binds to antioxidant-responsive elements (ARE) located
in the promoter of its target genes, including Cd36 [12].
Here we report that the combination of a high fructose intake and
PPARβ/δ deﬁciency increases CD36 protein levels via Nrf2, a process
that promotes inﬂammation and glucose intolerance.
2. Methods
2.1. Materials
GW501516 was purchased from Alexis Biochemicals (Lausen,
Switzerland). All other chemicals, except where speciﬁed, were from
Sigma-Aldrich (St. Louis, MO).
2.2. Animals and treatments
Mice were maintained under standard conditions of illumination
(12-h light/dark cycle) and temperature (21 ± 1 °C). Food and water
were provided ad libitum. All procedures were conducted in accordance
with the principles and guidelines established by the University of
Barcelona Bioethics Committee, as stated in Law 5/21 July 1995 passed
by the Generalitat de Catalunya and the Commission de Surveillance
de l'Expérimentation Animale of the Canton of Vaud (Switzerland).
Four- to ﬁve-month-old male PPARβ/δ knockout mice and control
mice (PPARβ/δ+/+, wild-type) with the same genetic background
(C57BL/6X129/SV) and an initial weight of 20–25 g were fed a standard
diet. The generation of PPARβ/δ nullmicehas been described previously
[14]. In addition to normal chow, the mice were fed either a 30%
fructose solution or plain tap water for 12 weeks, as previously de-
scribed [15,16].
Before the end of the treatments, a glucose tolerance test was per-
formed on mice after fasting for 4 h. Animals received 2 g/kg body
weight of glucose by intraperitoneal injection and blood was collected
from the tail vein after 0, 15, 30, 60 and 120 min. The body weight of
the mice was measured regularly during the treatment period. At the
end of the treatments, the mice were killed under isoﬂurane anesthesia
and samples of liver and epididymalwhite adipose tissuewere collected
and frozen in liquid nitrogen, and then kept at−80 °C.2.3. Measurement of malondialdehyde in white adipose tissue samples
The content of malondialdehyde (MDA), a marker of lipid peroxida-
tion, was determined using the lipid peroxidation (MDA) assay kit
(Sigma) in adipose tissue.
2.4. Cell culture
The human Simpson–Golabi–Behmel Syndrome (SGBS) cell line of
preadipocytes was induced to differentiate to mature adipocytes as
described previously [17]. During the differentiation process glucose
in the medium was reduced from 17 to 5 mmol/l and adipocytes were
exposed to either 25 mmol/l fructose or mannitol as a control, in order
to rule out the possibility that the effects of fructose were not the result
of an increase in the osmotic pressure, in the presence or absence of
either 10 μmol/l GW501516 (PPARβ/δ agonist) or 10 μmol/l GSK0660
(PPARβ/δ antagonist).
3T3-L1 preadipocytes (ATCC)were grown to conﬂuence in Dulbecco's
Modiﬁed Eagle's Medium (DMEM) supplemented with 10% bovine calf
serum. Two days after conﬂuence (day 0), differentiation of the 3T3-L1
cells was induced in DMEM containing 10% fetal bovine serum (FBS),
methylisobutylxanthine (500 μM), dexamethasone (0.25 μM), and insu-
lin (5 μg/ml) for 48 h. The cells were then incubated in 10% FBS/DMEM
with insulin for three days and this was then replaced with FBS/DMEM.
The medium was changed every 2 days. Fat droplets were observed in
more than 90% of the cells after day 10. The adipocytes were then
exposed to 25 mmol/l fructose or mannitol as a control in the presence
or absence of 10 μmol/l GW501516 or 0.5 μmol/l trigonelline. After incu-
bation, RNA, whole cell lysates, and both cytosolic and nuclear protein
extracts were extracted from the cells as described below.
2.5. RNA preparation and quantitative RT-PCR
Relative levels of speciﬁc mRNAs were assessed by real-time reverse
transcription-polymerase chain reaction (RT-PCR), as previously de-
scribed [18]. Total RNAwas isolated using the Ultraspec reagent (Biotecx,
Houston, TX). RNA sampleswere cleaned (NucleoSpin RNA II; Macherey-
Nagel, Düren, Germany) and checked for integrity by agarose gel electro-
phoresis. The total RNA isolated using this methodwas not degraded and
free from protein and DNA contamination. Reverse transcription was
performed from 0.5 μg total RNA using Oligo(dT)23 and M-MLV Reverse
Transcriptase (Invitrogen, San Diego, CA). The PCR reaction contained
10 ng of reverse-transcribed RNA, 2× IQTM SYBRGreen Supermix
(BioRad, Barcelona, Spain) and 900 nM of each primer. The PCR assays
were performed on a MiniOpticonTM Real-Time PCR system (BioRad).
Thermal cycling conditions were as follows: activation of Taq DNA
polymerase at 95 °C for 10 min, followed by 40 cycles of ampliﬁcation
at 95 °C for 15 s and at 60 °C for 1min. Primer Express Software (Applied
Biosystems, Foster City, CA)was used to design the primers (Supplemen-
tal Table S1). Optimal primer ampliﬁcation efﬁciency for each primer set
was assessed and a dissociation protocol was carried out to ensure a
single PCR product. The results for the expression of speciﬁc mRNAs are
always presented relative to the expression of the control gene.
2.6. Isolation of nuclear extracts
Nuclear extracts were isolated was performed as described
elsewhere [10].
2.7. Histological studies
White adipose tissue was ﬁxed in paraformaldehyde and embedded
in parafﬁn blocks using conventional histological techniques. Parafﬁn
sections were cut at 10 μm, deparafﬁnized in xylene and rehydrated to
water by ethanol at different percentages (100, 96, 80, 70 and 50).
After hematoxylin–eosin staining of the tissue preparations, images
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magniﬁcation. The cell area of 260–550 adipocytes per treatment
group was measured with the image analysis program ImageJ 1.42
(Bethesda, MD) to determine the average cell size and size distribution
for each experimental group.
For immunohistochemistry, parafﬁn sections were deparafﬁnized
and rehydrated as described above. Slides were blocked and perme-
abilized with PBS containing 1% bovine serum albumin (BSA) and 0.1%
Triton X-100 for 20 min. After two 5-min washes in PBS, the slides
were incubated with the primary antibody for Cd11b (Millipore,
Bedford, MA) overnight at 4 °C. Theywere thenwashed again and incu-
bated for 1 h at room temperature in the dark with Alexa Fluor second-
ary antibody. After washing again, nuclear staining was performed by
incubating the slides in Hoechst (H-33258, Fluka, Madrid, Spain) at
2 μg/ml in PBS for 10 min at room temperature in the dark. Finally, the
slides were washed, mounted using Prolong Gold (Invitrogen) anti-
fademedium, allowed to dry overnight at room temperature and stored
at 4 °C. Images were acquired with an Olympus BX61 epiﬂuorescence
microscope.
2.8. Immunoblotting
To obtain total proteins, adipose tissue and adipocytes were homog-
enized in RIPA lysis buffer with 5mMNaF, 1 mM phenylmethylsulfonyl
ﬂuoride, 10 mM sodium orthovanadate and 5.4 μg/ml aprotinin at 4 °C
for 30 min. The homogenate was centrifuged at 17,000 g for 30 min at
4 °C. Protein concentration was measured by the Bradford method.
Total proteins (30 μg) were separated by SDS-PAGE on 10% separation
gels and transferred to Immobilon polyvinylidene diﬂuoridemembranes
(Millipore). Western blot analysis was performed using antibodies
against total and phospho-AKT (Ser473), total and phospho-JNK
(Thr183/Tyr185), phospho-c-JUN (Ser73) (Cell Signaling Technology
Inc., Danvers, MA), total c-JUN, LOX-1, Nrf2, NQO1 (Santa Cruz
Biotechnology, Santa Cruz, CA), CD36 (Novus Biologicals, Littleton,
CO), and β-actin (Sigma-Aldrich). Detection was achieved using the
EZ-ECL chemiluminescence detection kit (Biological Industries Israel
Beit-Haemek Ltd., Kibbutz Beit-Haemek, Israel). The equality of the
protein loading was assessed using Ponceau S staining. The size of the
proteins detected was estimated using protein molecular-mass
standards (Life Technologies, Grand Island, NY).
2.9. Oxidized LDL
Serum levels of oxLDL were analyzed by ELISA (USCN Life Science,
Houston, TX).
2.10. Statistical analysis
Results are expressed as mean ± S.D. of four to six separate
experiments. Signiﬁcant differences were established by one-way
ANOVA, using the GraphPad Instat program (GraphPad Software
V2.03) (GraphPad Software Inc., San Diego, CA). When signiﬁcant dif-
ferences were found, the Tukey–Kramer multiple comparisons post-
test was applied. Differences were considered signiﬁcant at p b 0.05.
3. Results
3.1. Fructose exacerbates glucose intolerance in PPARβ/δ-deﬁcient mice
Water-fed PPARβ/δ-deﬁcient mice showed a lower bodyweight and
liver weight than wild-type mice, while fructose intake signiﬁcantly
increased both parameters in the PPARβ/δ-deﬁcient mice only (Fig. 1A
and B). As expected, the increase in both parameters was compensated
for in the liver weight–body weight ratio (Supplementary Fig. 1).
Surprisingly, fructose feeding did not signiﬁcantly increase liver triglyc-
eride accumulation in wild-type mice, suggesting that the geneticbackground of these mice might be resistant to hepatic steatosis. How-
ever, this protective effect observed in fructose-fed wild-type mice dis-
appeared in fructose-fed PPARβ/δ-deﬁcient mice, since carbohydrate
intake resulted in a marked accumulation of triglycerides in the liver
(~2-fold increase, p b 0.05) compared to water-fed PPARβ/δ-deﬁcient
mice (Fig. 1C). When subjected to a glucose-tolerance test, which
evaluates the capacity of the body to adjust glucose levels after an
acute glucose injection, water-fed PPARβ/δ-deﬁcient mice were
glucose-intolerant compared to wild-type mice, as demonstrated
by the signiﬁcant increase in the area under the curve (AUC)
(Fig. 1D and E). Interestingly, fructose intake signiﬁcantly exacerbated
this increase (p b 0.05 vs.water-fed PPARβ/δ-deﬁcientmice), indicating
that fructose potentiates glucose intolerance in these mice.
3.2. Fructose-induced adipocyte hypertrophy is exacerbated in
PPARβ/δ-deﬁcient mice
It has been well established that the larger the adipocyte, the less
sensitive it is to insulin [19]. When we examined the effects of fructose
on cell size in vivo we observed that adipocytes from water-fed wild-
type mice were larger (63% adipocytes b 2000 μm2) than those of
water-fed PPARβ/δ-deﬁcient mice (87% adipocytes b 2000 μm2)
(Fig. 2A and B), which is consistent with a previous study reporting
that PPARβ/δ-null mice contain smaller adipocytes than wild-type mice
[20]. It is worth noting that fructose feeding led to an increase in the
size of the adipocytes in wild-type mice (21% adipocytes b 2000 μm2)
and that this increase was even higher in PPARβ/δ-deﬁcient mice (9.5%
adipocytes b 2000 μm2). These ﬁndings indicate that, despite the lack
of induction of triglyceride accumulation in the liver of wild-type mice,
fructose led to adipocyte hypertrophy in these mice and this increase
was exacerbated in PPARβ/δ-deﬁcient mice.
3.3. Increased pro-inﬂammatory cytokine and chemokine expression
and macrophage inﬁltration in white adipose tissue from fructose-fed
PPARβ/δ-deﬁcient mice
Adipocyte size is an important determinant of the expression and
secretion of pro-inﬂammatory adipokines, which is greater in larger
adipocytes than in small or medium-sized cells [21,22]. Thus, we next
evaluated whether the changes in the size of the adipocytes were ac-
companied by changes in the expression of pro-inﬂammatory cytokines
and chemokines. The expression of Tnf-α was signiﬁcantly increased
in the white adipose tissue of fructose-fed PPARβ/δ-deﬁcient mice
(Fig. 3A). Since increased macrophage inﬁltration in adipose tissue
is an important component of the chronic inﬂammatory process in-
volved in the development of insulin resistance [23] and monocyte
chemoattractant protein (MCP-1) is a key chemokine involved in the re-
cruitment of macrophages, we measured its expression. Mcp-1mRNA
levels were strongly enhanced (p b 0.05) (Fig. 3B) in the white adipose
tissue of fructose-fed PPARβ/δ-deﬁcient mice. In agreement with
this, the expression of the macrophage markers F4/80 and Cd68 was
signiﬁcantly increased in white adipose tissue from fructose-fed
PPARβ/δ-deﬁcient mice (Fig. 3C and D). To conﬁrm the increased
macrophage content within adipose tissue, we performed immunohis-
tochemistry with a Cd11b antibody. Only in white adipose tissue from
fructose-fed PPARβ/δ-deﬁcient mice did we observe Cd11b-positive
crown-like structures, hallmarks of adipose tissue inﬂammation
(Fig. 3E).
An important feature of adipose tissue inﬂammation and insulin
resistance is the predominance of a classic M1 pro-inﬂammatory mac-
rophage phenotype,which is amajor source of inﬂammatorymediators,
such as TNF-α and MCP-1, vs. an M2 anti-inﬂammatory adipose tissue-
resident macrophage. Interestingly, it has been reported that PPARβ/δ
regulates adipose tissue-resident macrophages thus leading toward
the anti-inﬂammatory M2 phenotype [20]. When we analyzed the ex-
pression of two M2 macrophage markers, interleukin 10 (Il-10) and
Fig. 1. Fructose exacerbates glucose intolerance in PPARβ/δ-deﬁcient mice. Wild-type (WT) and PPARβ/δ-deﬁcient mice (PPARβ/δ−/−) were fed with either water or water containing
30% fructose for eight weeks. A, body weight. B, liver weight. C, hepatic triglyceride content. D, glucose tolerance test. E, area under the curve (AUC). Data are expressed as mean ±
S.D. (6 mice per group). ap b 0.05 vs.water-fed WT mice. bp b 0.05 vs. fructose-fed WT mice. cp b 0.05 vs.water-fed PPARβ/δ−/−mice.
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that the expression of bothmarkerswas signiﬁcantly reduced in PPARβ/
δ-deﬁcient mice compared to wild-type mice, which is consistent
with the results of Kang et al. (2008) [20] (Fig. 3F and G). However,
fructose-feeding did not exacerbate these changes, making it unlikely
that polarization of macrophages was responsible for the increase in
inﬂammation and glucose intolerance observed in the fructose-fed
PPARβ/δ-deﬁcient mice.
3.4. Increased activation of the oxLDL-CD36-JNK pathway in white adipose
tissue from fructose-fed PPARβ/δ-deﬁcient mice
Given that oxLDL promotes a CD36-dependent insulin resistance
phenotype in adipocyteswhich involves inﬂammation andmacrophage
inﬁltration in adipose tissue [11], we evaluated serum oxLDL levels.
Mice deﬁcient in PPARβ/δ exhibited a signiﬁcant increase in serum
levels of oxLDL compared to wild-type mice, whereas fructose intake
did not exacerbate the levels of oxLDL (Fig. 4A). In agreement with
this, the protein levels of the lectin-like ox-LDL receptor-1 (LOX-1), a
receptor up-regulated by oxLDL [24], were increased similarly in
water and fructose fed PPARβ/δ deﬁcient mice (Fig. 4B). Activation of
the oxLDL-CD36-JNK pathway depends on CD36, since it has been
reported that the absence of this scavenger receptor protects mice
against high-fat diet-induced inﬂammation and insulin resistance [11].
When we measured CD36 protein levels, we observed an increase in
water-fed PPARβ/δ-deﬁcient mice compared to wild-type mice fedwith either water or fructose (Fig. 4C). This suggests that the absence
of this nuclear receptor increases CD36 protein levels in adipose tissue.
It is worth noting that when the deﬁciency of PPARβ/δ was combined
with fructose feeding, a signiﬁcant increase was observed compared to
water-fed PPARβ/δ-deﬁcient mice, suggesting that fructose intake
causes an additional increase in CD36 protein levels in these mice.
Interestingly, only fructose-fed PPARβ/δ-deﬁcient mice exhibited a
signiﬁcant increase in Cd36mRNA levels (Fig. 4D), suggesting that the
additional increase in CD36 protein levels observed in this group
might involve a transcriptional mechanism. In agreement with the
changes in CD36 protein levels, JNK2 phosphorylation was increased
in water-fed PPARβ/δ-deﬁcient mice and this increase was signiﬁcantly
higher in fructose-fed PPARβ/δ-deﬁcientmice (Fig. 4E). Consistent with
this, the fructose-fed PPARβ/δ-deﬁcient mice displayed an increase in
phospho-c-Jun levels (Fig. 4F), a downstream target of JNK, as well as
in the expression of activated transcription factor 3 (Atf-3) (Fig. 4G), a
genewhich is under the control of the JNK-activated transcription factor
activator protein 1 (AP-1) [25]. Although Atf3 expression is also en-
hanced following endoplasmic reticulum (ER) stress, no increase was
observed in other markers of this process, such as glucose-regulated
protein 78 (Grp78/Bip) or CCAAT/enhancer-binding protein homolo-
gous protein (Chop) mRNA levels (data not shown). This suggests that
the increase in Atf3 expression was not the result of an increase in ER
stress. Overall, these ﬁndings suggest that, although PPARβ/δ-
deﬁciency leads to enhanced oxLDL levels, only the combination of
this genotype with fructose intake reaches CD36 protein levels
Fig. 2. Fructose increases adipocyte hypertrophy. A, representative microphotographs of
hematoxylin and eosin (H&E) staining of white adipose tissue. B, quantiﬁcation of adipo-
cyte size. Data are expressed as frequency (%). Results are presented as mean ± S.E.
Adipocyte diameters were measured in ﬁve random ﬁelds of adipose tissue sections
from three mice per group. The total adipocyte number was 500 per group.
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sion of inﬂammatory markers.
3.5. PPARβ/δ activation prevents the fructose-induced increase in CD36
protein levels and insulin signaling
Since CD36 is crucial in the oxLDL-mediated activation of JNK, in-
ﬂammation and insulin resistance in adipocytes [11,26], we next stud-
ied the mechanisms responsible for the effects of fructose and PPARβ/
δ on CD36 protein levels. We took advantage of the human SGBS adipo-
cytes. These cells have a high capacity for adipose differentiation and,
therefore, represent a unique tool for studying human fat cell develop-
ment andmetabolism [17].Whenwe examined the CD36 protein levels,
we observed that adipocytes exposed to 25 mM fructose exhibited an
increase in protein levels compared to those in isosmotic control exper-
iments carried out with mannitol (Fig. 5A). This increase was slightly
higher in cells exposed to fructose plus the PPARβ/δ antagonist
GSK0660, although the differences did not reach statistical signiﬁcance,
when compared to fructose alone. However, when cells were exposed
to fructose in the presence of the PPARβ/δ activator GW501516, CD36
protein levels were reduced even below the control levels. Although
PPARγ is a master regulator of Cd36 [27], the changes induced byfructose seemed not to be related to this nuclear receptor, since no
changes were observed in PPARγ protein levels following fructose ex-
posure. Then we examined whether PPARβ/δ activation by GW501516
was able to prevent fructose-induced insulin resistance by assessing
insulin-stimulated AKT phosphorylation. Exposure to fructose reduced
insulin-stimulated AKT phosphorylation compared to that of cells
exposed only to mannitol (Fig. 5B). Notably, cells exposed to fructose
co-incubated with GW501516 displayed an important recovery of AKT
phosphorylation. Similar results were obtained with murine 3T3-L1
adipocytes (Fig. 5C). Next, we evaluated the potential mechanism by
which PPARβ/δ activation might increase AKT phosphorylation and
prevent the increase in CD36 caused by fructose. Since previous studies
have reported that activation of the transcription factor Nrf2
upregulates Cd36 expression in 3T3-L1 cells [12], we explored the con-
tribution of this transcription factor to the changes in CD36 protein
levels observed in our conditions by using theNrf2 inhibitor trigonelline
[28]. Nrf2 activation seems to play an important role in fructose-
induced insulin resistance in adipocytes since inhibition of this tran-
scription factor with trigonelline completely prevented the decrease in
insulin-stimulated AKT phosphorylation caused by exposure to this
carbohydrate (Fig. 5D). Interestingly, similarly to trigonelline, the
PPARβ/δ agonist GW501516 abolished the increase in Nrf2 caused by
fructose in adipocytes, suggesting that PPARβ/δ activation reduces
CD36 protein levels in fructose-exposed adipocytes by preventing the
increase in nuclear Nrf2 levels (Fig. 5E). This protein is usually detected
as a dimer of 90–110 kDa. However, in our 3T3-L1 adipocytes Nrf2 was
detected at 56 kDa in agreementwith a previous study [29]. In addition,
Nrf2 inhibition by trigonelline abolished the increase in CD36 protein
levels caused by fructose in adipocytes (Fig. 5F), conﬁrming that
fructose-induced CD36 up-regulation involves Nrf2. In agreement
with the changes in Nrf2, the protein levels of the well-described
Nrf-2 target gene NAD(P)H:quinone oxidoreductase 1 (Nqo1) [30]
were increased by fructose and this increase was prevented by co-
incubation with trigonelline (Fig. 5G). Finally, we examined the protein
levels of Nrf2 and NQO1 in mice. Phosphorylated levels of Nrf2 are an
indicator of the activity of this transcription factor [31] andwe observed
that Nrf2was activated in thewhite adipose tissue of PPARβ/δ-deﬁcient
mice since enhanced nuclear levels of phosphorylated Nrf2 (~110 kDa)
were detected (Fig. 5H). Similarly, NQO1 protein levels were increased
only in the white adipose tissue of PPARβ/δ-deﬁcientmice and that this
increase was exacerbated by fructose feeding (Fig. 5I). Moreover, the
oxidative stress status measured by the lipid peroxidized product
MDA was increased in fructose-fed mice, but no signiﬁcant differences
were observed between fructose-fed wild-type and PPARβ/δ-deﬁcient
mice (Fig. 5J).
4. Discussion
According to the steps proposed in the development of adipose
tissue inﬂammation and insulin resistance [32], hypertrophic adipo-
cytes initially begin to secrete low levels of TNF-α, which stimulate
preadipocytes to produce MCP-1 [33]. As a result of the increase in
MCP-1, macrophages inﬁltrate into adipose tissue. Macrophages, along
with adipocytes and other cells, drive a vicious cycle of macrophage in-
ﬁltration and pro-inﬂammatory cytokine production. These inﬂamma-
tory cytokines, such as TNF-α, activate JNK and IKK serine-kinases,
which promote phosphorylation of IRS-1 on Ser307 (Ser312 in human
IRS-1), leading to inhibition of insulin receptor signaling and insulin re-
sistance. A new recent player in this scenario is CD36 [11,32,34]. Several
pathological ligands, including oxLDL, can signal via CD36 and thereby
affect both inﬂammatory and insulin signaling pathways in adipocytes.
Our ﬁndings suggest that fructose intake in PPARβ/δ-deﬁcient mice
leads to adipocyte hypertrophy, which is accompanied by increased in-
ﬂammation and macrophage inﬁltration, and increased glucose intoler-
ance through a mechanism that could involve over activation of the
oxLDL-CD36-JNK pathway. Of note, our ﬁndings also point to Nrf2 as a
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Fig. 4. Increased activation of the oxLDL-CD36-JNK pathway in fructose-fed PPARβ/δ-deﬁcient mice. A, oxLDL serum levels. Analysis of LOX-1 (B) and CD36 (C) protein levels by immu-
noblotting. D, Cd36mRNA levels. Cell lysates were assayed byWestern-blot analysiswith antibodies against total and phospho-JNK1/2 (E) and total and phosphor-c-Jun (F). Immunoblots
from four separate experiments were quantiﬁed and are presented in the corresponding bar graphs. G, Atf-3mRNA levels. Graphs represent the quantiﬁcation of the Aprt-normalized
mRNA levels. Data are expressed as mean ± S.D. (6 mice per group). ap b 0.05 vs.water-fed WT mice. bp b 0.05 vs. fructose-fed WT mice. cp b 0.05 vs.water-fed PPARβ/δ−/−mice.
1055E. Barroso et al. / Biochimica et Biophysica Acta 1852 (2015) 1049–1058key transcription factor involved in fructose-induced CD36 levels and
insulin resistance in adipocytes.
The ﬁndings of this study show that feeding fructose to PPARβ/δ-
deﬁcient mice led to an increase in weight gain and hepatic steatosis,
whichwas not observed in wild-type animals. We do not know the rea-
son for the lack of effects of fructose on these parameters in wild-type
animals, although the different genetic background (C57BL/6X129/SV)
compared to previous studies (C57BL/6 background) and age could be
involved, since a recent study reported that fructose feeding in young
C57BL/6 mice did not negatively affect ﬁnal body weight [35]. The
emergence of these effects in fructose-fed PPARβ/δ-deﬁcient mice sug-
gests that the presence of this nuclear receptor protects against these
phenotypic manifestations. The lack of an effect of fructose on hepatic
steatosis did not extend to other tissues, such as white adipose tissue,
thereby conﬁrming that the treatment with fructose supplementation
functioned as intended. Thus, fructose feeding elicited adipocyteFig. 3. Increased inﬂammation and macrophage inﬁltration in fructose-fed PPARβ/δ-deﬁcien
quantiﬁcation of the Aprt-normalized mRNA levels. E, representative images of CD11b immu
are expressed as mean ± S.D. (6 mice per group). ap b 0.05 vs.water-fed WT mice. bp b 0.05 vhypertrophy in wild-type mice, which is consistent with previous stud-
ies [36], and, to a greater extent, in PPARβ/δ-deﬁcient mice. The pres-
ence of larger adipocytes in the white adipose tissue of fructose-fed
PPARβ/δ-deﬁcient mice was accompanied by an increase in the expres-
sion of Tnf-α andMcp-1, butwasnot in fructose-fedwild-typemice. This
suggests that besides adipocyte hypertrophy, additional mechanisms
are responsible for the increase in the expression of the genes men-
tioned. Consistent with the increase inMcp-1 expression, we observed
enhanced macrophage inﬁltration in the white adipose tissue of
fructose-fed PPARβ/δ-deﬁcient mice. This inﬁltration of macrophages
can also be responsible for part of the increase in the expression of
pro-inﬂammatory cytokines. It is worth emphasizing that MCP-1 con-
tributes to macrophage inﬁltration into adipose tissue, insulin resis-
tance and hepatic steatosis [37,38]; which are all features observed in
fructose-fed PPARβ/δ-deﬁcient mice. Despite PPARβ/δ being able to
regulate macrophage polarization [20], our ﬁndings rule out thet mice. Tnf-α (A),Mcp-1 (B), F4/80 (C) and Cd68 (D) mRNA levels. Graphs represent the
nohistochemistry of the white adipose tissue. Il-10 (F) and Mgl-1 (G) mRNA levels. Data
s. fructose-fed WT mice. cp b 0.05 vs.water-fed PPARβ/δ−/−mice.
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crease in inﬂammation and glucose intolerance in fructose-fed PPARβ/
δ-deﬁcient mice.
OxLDL activates JNK in adipocytes and disrupts insulin signaling in a
CD36-dependentmanner [11]. PPARβ/δ-deﬁcient mice fed either water
or fructose exhibited increased oxLDL levels, suggesting that PPARβ/δ
deﬁciency increases these modiﬁed lipoproteins. As far as we know,
this is the ﬁrst study to report that PPARβ/δ deﬁciency increases
oxLDL and reveals a new pharmacological target that could be used to
reduce levels of oxLDL, which are strongly associatedwith atherosclero-
sis, and diabetes and its complications [39]. Despite it having been
reported that fructose feeding can increase the plasma levels of oxLDL
in humans [2,40], we did not observe an additional increase in
fructose-fed vs. water-fed PPARβ/δ-deﬁcient mice.
CD36 is considered a PPARβ/δ target gene [41], although activation
of PPARβ/δmay yield different tissue-speciﬁc results. Thus, it has been
reported that activation of PPARβ/δ results in enhanced CD36 levels in
skeletal muscle [42]; whereas in liver, PPARβ/δ agonists reduce Cd36
expression [41]. In agreement with this PPARβ/δ-dependent regulation
of CD36, water-fed PPARβ/δ-deﬁcient mice showed enhanced CD36
protein levels in white adipose tissue. Interestingly, fructose-fed
PPARβ/δ-deﬁcient animals exhibited signiﬁcantly higher CD36 protein
levels than water-fed mice. This fructose-induced increase is consistent
with a previous study that reported that fructose intake (60% for
8 weeks) increases CD36 protein levels in the white adipose tissue of
rats [43]. Our in vitro studies in SGBS adipocytes conﬁrmed that fructose
increases CD36 protein levels.
The additional increase in CD36 protein levels resulting from
fructose in PPARβ/δ-null mice compared to water-fed PPARβ/δ-null
mice seems to be dependent on the transcriptional activation of the
Cd36 gene, since Cd36 mRNA levels were increased in the former.
Since it has been reported that Nrf2 increases Cd36 expression in 3T3-
L1 cells [12], we focused on this transcription factor. Our in vitroﬁndings
conﬁrmed that fructose increased the nuclear protein levels of Nrf2
and that the increase in CD36 protein levels caused by fructose was de-
pendent on this transcription factor, inasmuch as the Nrf2 inhibitor
trigonelline reversed the increase. Notably, the PPARβ/δ agonist
GW501516 completely abolished the increase in Nrf2 induced by
fructose, which suggests that the lack of PPARβ/δmay contribute to an
increase in Nrf2 transcriptional activity. In agreement with this, white
adipose tissue from PPARβ/δ-null mice showed enhanced phosphory-
lated protein levels of Nrf2 and of its target gene Nqo1 and the increase
of the latter was higher in those mice fed fructose than in those fed
water, suggesting that the lack of PPARβ/δ and fructose synergistically
contribute to increase CD36 levels through Nrf2. Notwithstanding the
foregoing, we did not observe a higher increase in phosphorylated
Nrf2 levels in fructose-fed PPARβ/δ-deﬁcient compared to water-fed
PPARβ/δ-deﬁcient mice. A similar behavior has been described previ-
ously in 3T3-L1 cells, where oxLDL treatment increased CD36 protein
levels for 5 days, whereas nuclear Nrf2 levels peaked at 5 h following
oxLDL exposure, but returned to basal levels at 7 h [12]. We do not
know the reason for this, but it has been reported that CD36 inhibits
Nrf2 nuclear localization [44]. Thus, sustained increase of CD36 in vivo
might activate this mechanism, causing a reduction in nuclear Nrf2
proteins.
Our ﬁndings also support an important role for Nrf2 in fructose-
induced insulin resistance in adipocytes, since it was completely
reversed by the Nrf2 inhibitor trigonelline. In fact, Nrf2-null mice have
decreased white adipose tissue mass and smaller adipocyte formationFig. 5. PPARβ/δ-activation prevents the increase in CD36 protein levels in adipocytes caused
25 mM fructose or mannitol with or without 10 μmol/l GW501516, 10 μmol/l GSK0660 or 0.5
for the last 10min. Cell lysates from human SGBS adipocytes were assayed forWestern-blot ana
AKT (Ser473) (B) in human SGBS. Cell lysates frommurine 3T3-L1 adipocytes were assayed for
nuclear Nrf2 (E), CD36 (F) and NQO1 (G). Analysis of Nrf2 (H) and NQO1 protein levels by imm
mice (PPARβ/δ−/−) fed with either water or water containing 30% fructose. ap b 0.05 vs.water-and protection against weight gain and obesity than wild-type mice
[13]. Consistent with this, it has been reported that enhanced Nrf2
activity exacerbates insulin resistance in leptin-deﬁcient mice [45].
Given that CD36 is key for the activation of JNK in adipocytes by
oxLDL and for the disruption of insulin signaling [11], the differences
in CD36 protein levels in water-fed and fructose-fed PPARβ/δ-null
mice may result in enhanced metabolic alterations. Thus, although
the levels of oxLDL were similar in both water-fed and fructose-fed
PPARβ/δ-deﬁcient mice, the higher increase in CD36 protein levels in
the transgenic mice receiving fructose, might entail a higher ampliﬁca-
tion of the oxLDL-CD36-JNK pathway. Consistentwith this, we observed
increased JNK2phosphorylation in thewhite adipose tissue of PPARβ/δ-
deﬁcient mice fed with fructose, which resulted in an increase of its
downstream targets (phospho-c-jun and Atf3mRNA levels). Although
the JNK1 isoform has primarily been implicated in the development of
obesity and insulin resistance [46], JNK2 might also play a role as the
balance between JNK1 and JNK2, which inﬂuences total JNK activity,
and is a critical determinant of inﬂammatory cytokine production [47].
Although we have used a human adipocytic cell line to know the
relevance of the data obtained in murine models, one limitation of this
study is the lack of data from human samples to assess whether the
mechanism described in this study also operates in human beings and
contributes to exacerbating metabolic alterations.
In summary, our ﬁndings show that glucose intolerance in PPARβ/δ-
deﬁcient mice is associated with the generation of oxLDL and increased
CD36 protein levels in white adipose tissue. When this genotype was
combined with a chronic intake of fructose, increases in adipocyte
hypertrophy, inﬂammation, macrophage inﬁltration and glucose
intolerance were observed. Since previous studies have reported that
PPARβ/δ activity might be reduced in the white adipose tissue of
obese insulin-resistant patients [10], it might be interesting to study
whether inﬂammation and development of type 2 diabetes mellitus is
accelerated in obese high fructose consumers through the mechanism
reported in this study.
Supplementary data to this article can be found online at http://10.
1016/j.bbadis.2015.02.010.Transparency document
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